US FDA approves Roche's Actemra for previously treated RA - update
This article was originally published in Scrip
Executive Summary
The US FDA has approved Roche's first-in-class IL-6-receptor inhibiting monoclonal antibody Actemra (tocilizumab) for the treatment of moderate-to-severely active rheumatoid arthritis (RA) in patients who are unresponsive to TNF inhibitors. The drug will be available in the US from January 18th.